http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114028572-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0ee33b0e3e7398cf6fc957eeee59d510 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4196 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4196 |
| filingDate | 2021-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_396d603324f2de504ee7c6739117ee1c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66ed8cef37619c3019fa25b67ec56c62 |
| publicationDate | 2022-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-114028572-A |
| titleOfInvention | New application of MAT2A inhibitors for the treatment of asthma |
| abstract | The present invention provides a new application of MAT2A inhibitor for treating asthma. Specifically, the present invention provides the use of a MAT2A inhibitor in the preparation of a medicament for the treatment of asthma or its related diseases. The present invention also provides the use of a MAT2A inhibitor in the preparation of a preparation for inhibiting the biosynthesis of the universal methyl donor S-adenosylmethionine to inhibit the function of type 2 native lymphoid cells. The present invention also provides the use of a MAT2A inhibitor in the preparation of a preparation for inhibiting the function of type 2 innate lymphoid cells; preferably, the inhibiting the function of type 2 innate lymphoid cells comprises inhibiting or reducing type 2 innate lymphoid cells Cellular type 2 cytokine expression. The present invention also provides the application of targeting the methionine cycle in screening and/or preparing medicines for the treatment of asthma or its related diseases. |
| priorityDate | 2021-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 66.